| |
| |
|
| Insider
Information: |
Spiegelman Daniel K |
| Relationship: |
Director |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
155,668 |
|
|
Indirect Shares
|
6,673 |
|
|
| Direct
Value |
$5,222,943 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
162,341 |
|
|
| Total
Value |
$5,222,943 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
CV Therapeutics Inc |
CVTX |
SVP, CFO |
2009-04-09 |
67,489 |
2009-04-09 |
6,673 |
Premium* |
|
|
Cascadian Therapeutics, Inc |
CASC |
Director |
2018-03-09 |
0 |
2009-12-04 |
0 |
Premium* |
|
|
Biomarin Pharmaceutical Inc |
BMRN |
EVP, Chief Financial O... |
2019-04-30 |
47,686 |
2012-05-29 |
0 |
Premium* |
|
|
Relypsa Inc |
RLYP |
Director |
2016-09-01 |
0 |
2015-06-04 |
0 |
Premium* |
|
|
Myriad Genetics Inc |
MYGN |
Director |
2023-06-02 |
40,493 |
2020-05-27 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
180 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 8
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2015-04-30 |
4 |
A |
$51.26 |
$4,511 |
D/D |
88 |
79,366 |
0 |
- |
|
| RLYP |
Relypsa Inc |
Director |
– • – |
2015-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
2,250 |
2,250 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2015-10-31 |
5 |
A |
$51.26 |
$11,022 |
D/D |
215 |
28,444 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2016-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
72,633 |
101,077 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2016-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
16,640 |
63,933 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2016-04-29 |
4 |
A |
$51.26 |
$10,355 |
D/D |
202 |
64,135 |
0 |
- |
|
| RLYP |
Relypsa Inc |
Director |
– • – |
2016-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
2,250 |
3,487 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2016-10-31 |
4 |
A |
$68.44 |
$10,677 |
D/D |
156 |
43,100 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2017-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
12,247 |
30,347 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2017-03-22 |
4 |
A |
$0.00 |
$0 |
D/D |
12,200 |
26,671 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2017-04-28 |
4 |
A |
$70.30 |
$10,897 |
D/D |
155 |
26,826 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2018-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
12,529 |
70,129 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2018-02-26 |
4/A |
A |
$0.00 |
$0 |
D/D |
12,615 |
70,215 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2018-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
12,480 |
77,185 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2018-04-30 |
4 |
A |
$68.78 |
$11,487 |
D/D |
167 |
62,781 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2018-10-31 |
4 |
A |
$68.78 |
$12,037 |
D/D |
175 |
51,245 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2019-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
12,205 |
63,450 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2019-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
9,370 |
64,681 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2019-04-30 |
4 |
A |
$68.78 |
$12,106 |
D/D |
176 |
47,686 |
0 |
- |
|
| MYGN |
Myriad Genetics Inc |
Director |
– • – |
2020-05-27 |
4 |
A |
$0.00 |
$0 |
D/D |
20,562 |
20,562 |
0 |
- |
|
| MYGN |
Myriad Genetics Inc |
Director |
– • – |
2020-12-04 |
4 |
A |
$0.00 |
$0 |
D/D |
15,889 |
36,451 |
0 |
- |
|
| MYGN |
Myriad Genetics Inc |
Director |
– • – |
2021-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
12,848 |
26,268 |
0 |
- |
|
| MYGN |
Myriad Genetics Inc |
Director |
– • – |
2022-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
17,275 |
40,404 |
0 |
- |
|
| MYGN |
Myriad Genetics Inc |
Director |
– • – |
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
15,151 |
49,131 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2006-12-12 |
4 |
AS |
$12.92 |
$38,760 |
D/D |
(3,000) |
3,439 |
0 |
- |
|
180 Records found
|
|
Page 2 of 8 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
